Clinical Trial Search

Primary: Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2913.55; 2837.74…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 394 Participants

Primary: Percentage of Participants With Drug-related Adverse Events (AEs) On-treatment — 90.0; 60.0 Percentage of participants

Primary: Amputation-free Survival — 67.2 percentage of participants

Primary: Number of Participants With Drug-related Adverse Events — 0; 0; 0 Participants

Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4164.32; 4057.42…

Primary: Accuracy of 3D Echocardiography Based Measurements of Right Ventricular Size Compared to MRI Derived Values. — 187.1; 175.4; 205.0; 86.0 ml

Primary: Number/Percentage of Patients Who Achieved Corneal Epithelial Healing at NGF0120 Week 8 (EoT NGF0120=Baseline NGF0122) and Remained Healed at Month 24 and Month 30 of…

Primary: Overall Survival (OS) Rate — 82.7 Percentage of Participants

Primary: Number of Participants With Evidence of Soft Tissue-to-Bone Healing in the Shoulder — 106; 108 participants

Primary: The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24…

Primary: Adverse Events — 10 Participants

Primary: Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires — 3.4; 65.2 points on a…

Primary: Self Reported Reduction in Average Cigarettes Smoked Per Day at 12 Weeks — 5.2; 4.9 cigarettes per day

Primary: Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab — 9; 8; 8 Participants